Connect with us

Hi, what are you looking for?

United Kingdom

UK’s DSTL research behind trial of new blood test to predict sepsis

Queen Alexandra Hospital at Portsmouth. Photo: UK government

London, June 10 (MNN) Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of a blood test that could help to save thousands of UK lives a year by predicting sepsis days before patients show any symptoms, the UK’s Defence Science and Technology Laboratory said on Thursday.

The test, originally researched over 10 years at the DSTL is now being developed by government spin-out company Presymptom Health which believes it could save billions of pounds globally and improve clinical outcomes for sepsis patients.

Sepsis is the immune system’s overreaction to an infection or injury and is associated with life-threatening organ dysfunction. Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost 2 million patients admitted to hospital each year are thought to be at risk of developing the condition.

Presymptom Health believes the technology can predict whether a patient will develop sepsis around 3 days before symptoms appear, enabling clinicians to treat them much sooner and manage them more effectively.

Professor Dame Angela McLean, Chief Scientific Adviser for MOD, said: “The announcement today is a great step forward in finding potential new ways to tackle sepsis, which causes up to 48,000 deaths and significant life-changing effects in nearly 80,000 people in the UK every year. The seminal work led by Dstl, now taken forward by Presymptom Health, has the potential to provide the technology capable of detecting sepsis early, enabling more rapid treatment, and saving lives.”

The trials are being led by Dr Paul Schmidt and his team at Portsmouth Hospitals University NHS Trust, with two other sites anticipated to go live during the summer.

Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial.

The promising technology has received 2,00,000 pounds in funding from Ploughshare Innovations, which takes research created by world-leading government laboratories, such as DSTL, and commercialises it to deliver societal impact.

Iain Miller, CEO at Presymptom Health, said: “This test may represent a significant step in the prediction of sepsis. A substantial investment from Ploughshare Innovations has enabled us to rapidly develop this test to get to the clinical trial stage. We are very grateful for their backing, and for the support of the clinicians at Portsmouth Hospitals University NHS Trust. We are confident that this trial will confirm our test’s ability to provide vital and life-saving results when they are most needed.”

You May Also Like


Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.